Evidence Table K3: DISCRETE outcomes for class RETINOID (ORAL).

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
	K.02.01			**Isotretinoin**	**Placebo**	
269 ↑ Parallel Sev N=33		**Reduction in application due to side effects**		Cheilitis 1 Facial dermatitis 1 Artharlgia 1	Cheilitis 0 Facial dermatitis 0 Artharlgia 0	
	K.02.02			**Isotretinoin**	**Dapsone**	
276 Parallel Sev N=40		**Side effects**	Long (16	Cheilitis 17 Hypersensitivity reaction (withdraw) 0	Cheilitis 0 Hypersensitivity reaction (withdraw) 1	
	K.02.03			**Isotretinoin**	**Tetracycline hydrochloride**	
206 ↓ Parallel Sev N=30		**Integumentary side effects I**		Xerosis 15 Cheilitis/dry lips 15 Desquamation of skin 7 Atopecia 3	Xerosis 2 Cheilitis/dry lips 3 Desquamation of skin 0 Atopecia 0	
		Integumentary side effects II		Erythema 3 Pruritis 1 Dry hair 1 Skin flushing 1 Eczema 1	Erythema 0 Pruritis 0 Dry hair 2 Skin flushing 1 Eczema 0	
		Integumentary side effects III		Tender fingertips 1 Skin fissuring 1 Lesions crusting 1 Morbilliform eruption 0 Herpes simplex 0	Tender fingertips 0 Skin fissuring 0 Lesions crusting 0 Morbilliform eruption 1 Herpes simplex 1	
		Systemic reactions		Epistaxis 10 Dry nose 10 Increased thirst 0 Dry mouth 3 Indigestion 0	Epistaxis 0 Dry nose 1 Increased thirst 2 Dry mouth 1 Indigestion 1	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
206 ↓ Parallel Sev N=30		**Systemic reactions/Special senses**		Conjunctivtis 1 Pterguim 1 Photophobia 1 Decreased sweating 1	Conjunctivitis 0 Pterguim 0 Photophobia 0 Decreased sweating 0	
				Tiredness 0 Dry eyes 2	Tiredness 2 Dry eyes 0	
		Post-therapy back total lesions change	Long (24	Decreased 5 No change 8 Ok new lesion 2	Decreased 0 No change 10 Ok new lesion 5	
		Post-therapy chest total lesion change	Long (24	Decreased rate 2 No change 4 Ok rate at baseline 9	Decreased rate 0 No change 3 Ok rate at baseline 12	
	K.03.01			**Vitamin A**	**Placebo**	
12 ↑ Parallel N=80		**Overall change/dermatologist**	Mid (12)	Improved 10 No change 18 Worse 2	Improved 11 No change 9 Worse 21	
		Overall change/generalist	Mid (12)	Improved 24 No change 5 Worse 1	Improved 22 No change 8 Worse 1	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.